Metoprolol Retard Teva

Metoprolol succinate, the active ingredient in Metoprolol Retard Teva, is a beta‑blocker presented as an extended‑release tablet for oral use. It treats hypertension, chronic stable angina, heart failure with reduced ejection fraction, and is used after myocardial infarction.

GNH USA supplies Metoprolol Retard Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoprolol succinate is indicated for several cardiovascular conditions where beta‑1 adrenergic blockade improves outcomes. - Hypertension: reduces systolic and diastolic blood pressure by decreasing heart rate and cardiac output. - Chronic stable angina: lessens myocardial oxygen demand, relieving chest pain during exertion. - Heart failure (reduced ejection fraction): improves survival and reduces hospitalisations by lowering ventricular workload. - Post‑myocardial infarction: decreases the risk of recurrent infarction and arrhythmias by stabilising heart rhythm.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Fatigue: feeling unusually tired or weak. - Dizziness: light‑headedness, especially when standing quickly. - Bradycardia: slower than normal heart rate. - Cold extremities: reduced blood flow to hands and feet. - Gastrointestinal upset: nausea or abdominal discomfort.

Serious or Rare Side Effects: - Heart block: impaired electrical conduction requiring medical attention. - Severe bronchospasm: difficulty breathing, particularly in patients with asthma. - Hypotension: markedly low blood pressure causing fainting. - Depression or mood changes: new or worsening depressive symptoms. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

Before initiating therapy, consider patient‑specific factors and monitor appropriately. - Cardiac function: assess baseline heart rate and blood pressure. - Respiratory disease: use cautiously in patients with asthma or chronic obstructive pulmonary disease. - Diabetes: monitor blood glucose as beta‑blockade may mask hypoglycaemia symptoms. - Concomitant drugs: review other medications that affect heart rate or blood pressure. - Pregnancy and lactation: evaluate risk‑benefit ratio; data are limited. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Metoprolol succinate can interact with several drug classes, altering its efficacy or safety.

Major Interactions (Avoid): - Non‑selective beta‑blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): profound heart‑rate slowing and AV‑block. - CYP2D6 inhibitors (e.g., quinidine, paroxetine): increased metoprolol plasma levels.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: may mask hypoglycaemia signs. - NSAIDs: can reduce antihypertensive effect. - Diuretics: may potentiate orthostatic hypotension. - Antidepressants (tricyclics): enhanced bradycardic effect.